文献速递胸部肿瘤

避免肺癌放疗毒性:IASLC视角

Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective.
PubMed 文献 · J Thorac Oncol · 2022-05-29

本文总结胸部放疗已知毒性、降低毒性可行的技术进步,以及正在评估的降低毒性的新兴技术和生物标志物;指出III期剂量递增试验显示胸部关键器官过量剂量可负影响总生存。

要点

  • 胸部放疗毒性关注点在过去几十年发生显著变化。
  • 先进放疗和影像技术使降低毒性成为可能。
  • III期剂量递增试验显示胸部关键器官过量剂量可负影响总生存。

核心结论

  • 胸部关键器官接受过量剂量可对总生存产生负面影响。
  • 先进放疗和影像技术使降低毒性成为可能。
  • 正在评估新兴技术和生物标志物以进一步降低毒性。

研究设计与样本

  • IASLC视角的文献综述,总结胸部放疗已知毒性、技术进步及新兴技术和生物标志物。

主要发现

  • 肺癌治疗生存率显著改善。
  • III期剂量递增试验显示胸部关键器官过量剂量可负影响总生存。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Bucknell NW, Belderbos J, Palma DA, et al. Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. J Thorac Oncol. 2022. PMID: 35649502. doi:10.1016/j.jtho.2022.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。